Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24054520 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Fanny Seraphine Krebs und 9 weiteren Autor:innen. Beteiligte Einrichtung: Computer-Aided Molecular Engineering, Department of Oncology UNIL-CHUV, University of Lausanne, 1015 Lausanne, Switzerland. Hauptthemen laut MEDLINE: Skin Neoplasms, Melanoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The development of targeted therapies for non-BRAF p.Val600-mutant melanomas remains a challenge. Triple wildtype (TWT) melanomas that lack mutations in BRAF, NRAS, or NF1 form 10% of human melanomas and are heterogeneous in their genomic drivers. MAP2K1 mutations are enriched in BRAF-mutant melanoma and function as an innate or adaptive resistance mechanism to BRAF inhibition. Here we report the case of a patient with TWT melanoma with a bona fide MAP2K1 mutation without any BRAF mutations. We performed a structural analysis to validate that the MEK inhibitor trametinib could block this mutation. Although the patient initially responded to trametinib, he eventually progressed. The presence of a CDKN2A deletion prompted us to combine a CDK4/6 inhibitor, palbociclib, with trametinib but without clinical benefit. Genomic analysis at progression showed multiple novel copy number alterations. Our case illustrates the challenges of combining MEK1 and CDK4/6 inhibitors in case of resistance to MEK inhibitor monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Computer-Aided Molecular Engineering, Department of Oncology UNIL-CHUV, University of Lausanne, 1015 Lausanne, Switzerland.
- Ludwig Institute for Cancer Research, 1005 Lausanne, Switzerland.
- Service of Medical Oncology, 1700 Fribourg, Switzerland.
- Department of Laboratory Medicine and Pathology, Institute of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne University, 1011 Lausanne, Switzerland.
- Molecular Modelling Group, SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.
- Monash Medical Centre, Clayton, VIC 3168, Australia.
ORCID-Profile: Petros Tsantoulis, Bettina Bisig, Vincent Zoete, Krisztian Homicsko
Zitieren
APA
Krebs, F. S., Moura, B., Missiaglia, E., Aedo-Lopez, V., Michielin, O., Tsantoulis, P., Bisig, B., Trimech, M., Zoete, V., & Homicsko, K. (2023). Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054520
Vancouver
Krebs FS, Moura B, Missiaglia E, Aedo-Lopez V, Michielin O, Tsantoulis P, et al. Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054520
BibTeX
@article{Krebs2023,
author = {Krebs, Fanny Seraphine and Moura, Bianca and Missiaglia, Edoardo and Aedo-Lopez, Veronica and Michielin, Olivier and Tsantoulis, Petros and Bisig, Bettina and Trimech, Mounir and Zoete, Vincent and Homicsko, Krisztian},
title = {Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24054520}
}
EUVIMED